多肽与肿瘤耐药机制的研究进展  

Research progress on peptides and tumor drug resistance mechanisms

作　　者：李娜娜 苏亚娟[1] LI Nana;SU Yajuan(Department of Clinical Laboratory,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院检验科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2024年第4期748-754,共7页Journal of Modern Oncology

基　　金：哈尔滨医科大学附属肿瘤医院海燕科研基金(编号:JJZD2022-01)。

摘　　要：恶性肿瘤严重危害人类生命健康。随着对肿瘤发生发展和治疗的研究,患者的生存期、愈后等方面已取得很大进步。但是肿瘤的固有耐药和获得性耐药依然是肿瘤治疗过程中的巨大障碍。多肽在人体中分布广泛,参与多种生理病理过程。研究人员发现多肽在介导肿瘤耐药发生和缓解肿瘤耐药过程中都有参与。本文将对多肽介导肿瘤耐药和缓解肿瘤耐药的机制做一综述,以期为未来克服肿瘤细胞耐药提供新的思路。Malignant tumors seriously endanger human life and health.With the research on the development and treatment of tumors,great progress has been made in the survival and prognosis of patients.However,the inherent and acquired chemoresistance is still a huge obstacle in the treatment of tumors.Peptides widely distribute in the human tissues and participate in a variety of physiopathological processes.The researchers found that peptides are involved in both mediating chemoresistance and alleviating chemoresistance.This article will review the mechanism of peptides mediating chemoresistance and alleviating chemoresistance,in order to provide new ideas for overcoming chemoresistance in the future.

关 键 词：多肽 肿瘤 耐药性 机制 

分 类 号：R730.23[医药卫生—肿瘤]